.Pharmacolibrary.Drugs.D_Dermatologicals.D05B_AntipsoriaticsForSystemicUse.D05BB01_Etretinate.Etretinate .Pharmacolibrary.Drugs.D_Dermatologicals.D05B_AntipsoriaticsForSystemicUse.D05BB01_Etretinate.Etretinate| name: | Etretinate |
| ATC code: | D05BB01 | route: | oral |
| n-compartments | 2 |
Etretinate is a synthetic aromatic retinoid, formerly used for the treatment of severe, recalcitrant psoriasis and other keratinization disorders. Due to its long elimination half-life and teratogenic potential, it has been withdrawn or replaced by acitretin in many countries and is not commonly used today.
Pharmacokinetic parameters reported in healthy adult volunteers after oral administration.
Geiger, JM, et al., & Saurat, JH (1994). Teratogenic risk with etretinate and acitretin treatment. Dermatology (Basel, Switzerland) 189(2) 109–116. DOI:10.1159/000246811 PUBMED:https://pubmed.ncbi.nlm.nih.gov/8075435
Park, HD, et al., & Lee, SY (2009). A fully validated HPLC method for the simultaneous determination of acitretin and etretinate in plasma and its application to a pharmacokinetic study in healthy Korean subjects. International journal of clinical pharmacology and therapeutics 47(7) 476–482. DOI:10.5414/cpp47476 PUBMED:https://pubmed.ncbi.nlm.nih.gov/19640355
Pilkington, T, & Brogden, RN (1992). Acitretin : A Review of its Pharmacology and Therapeutic Use. Drugs 43(4) 597–627. DOI:10.2165/00003495-199243040-00010 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28421560